Syros Pharmaceuticals Inc (NAS:SYRS)
$ 0.257 -0.0145 (-5.34%) Market Cap: 6.90 Mil Enterprise Value: 9.24 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 34/100

Syros Pharmaceuticals Inc at JMP Securities Life Sciences Conference Transcript

May 16, 2023 / 02:00PM GMT
Release Date Price: $3.82 (+1.60%)
Jason Butler
JMP Securities - Analyst

Great. Good morning, everybody. Thank you for joining us again at the JMP Securities Life Science Conference. I'm Jason Butler, one of the biotech research analysts. Excited to start my morning off at least with Syros Pharmaceuticals.

Syros is a company developing novel therapeutics for primarily cancer indications and excited to be joined by the company's CEO, Nancy Simonian. So Nancy, thank you for being here and would love to just ask you to give a quick intro and a 30-second overview of Syros.

Nancy Simonian
Syros Pharmaceuticals - President & CEO

Great, Jason. Thank you so much for having us today. So Syros is a late-stage development company that's focusing on developing new standards of care for the frontline treatment of hematologic malignancies. We have two programs in three heme diseases, MDS, AML, and APL, all in targeted populations. We think they're very attractive opportunities where there's very high unmet medical need. We have multiple data catalysts coming up over the next 18 months and we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot